ARO-DIMERPA for adults with mixed high cholesterol and triglycerides

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/2 interventional study enrolls adults with mixed hyperlipidemia to receive single or multiple doses of ARO-DIMERPA or placebo and follows them for safety, tolerability, pharmacokinetics, and pharmacodynamics. Lipid endpoints include changes in LDL-C and triglycerides, with regular laboratory monitoring. The design includes placebo controls and predefined cohorts for single‑dose and multiple‑dose administration. Participants must follow diet counseling per investigator judgment and comply with contraception rules if of childbearing potential.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing to follow diet counseling as per Investigator judgment based on local standard of care
* Specific fasting TG, LDL-C, and non-high density lipoprotein cholesterol levels at Screening
* Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later; participants must not donate sperm or eggs during the study and for at least 90 days following the end of the study or last dose of study drug whichever is later

Exclusion Criteria:

* Current use or use within last 365 days or within 5-half-lives before Day 1 based on plasma PK, whichever is longer, of any hepatocyte-targeted siRNA
* Current use or use within last 90 days or within 5-half-lives before Day 1 based on plasma PK, whichever is longer, of any antisense oligonucleotide therapy
* Current use or use within last 60 days from Day 1 of any PCSK9 inhibitor monoclonal antibodies (eg, evolocumab or alirocumab)
* Uncontrolled hypertension
* History of bleeding diathesis or coagulopathy
* Current diagnosis of nephrotic syndrome

Note: Additional inclusion/exclusion criteria may apply per protocol.

Where it's running

• Research Site 7
  Charlestown, New South Wales, Australia Recruiting
• Research Site 5
  Morayfield, Queensland, Australia Recruiting
• Research Site 8
  East Melbourne, Victoria, Australia Recruiting
• Research Site 4
  Melbourne, Victoria, Australia Recruiting
• Research Site 9
  Perth, Western Australia, Australia Recruiting
• Research Site 11
  Clayton, Australia Recruiting

Study contacts

• Study coordinator: Medical Monitor
• Email: ARODIMERPA-1001@arrowheadpharma.com
• Phone: 626-304-3400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating HST101 for lowering cholesterol in Chinese patients

  This study is testing if a new drug called HST101 can lower cholesterol levels in Chinese patients who have high cholesterol and are at risk for heart disease.

  Recruiting at 17 sites Phase 3 Hasten Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 17 other locations · NCT06568471

• Enlicitide (MK-0616) for adults with high cholesterol in India

  This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.

  Recruiting at 2 sites Phase 3 Merck Sharp & Dohme LLC · Belagavi, Karnataka and 1 other locations · NCT07821944

• HRS-7249 extension study for people with high triglycerides

  This extension study tests whether repeat injections of HRS-7249 are safe and keep triglyceride levels low in adults who previously completed the parent study or have high fasting triglycerides.

  Recruiting at 2 sites Phase 2 Fujian Shengdi Pharmaceutical Co., Ltd. · Jinan, Shandong and 1 other locations · NCT07799688

• Bacillus subtilis and Enterococcus faecium Probiotic Plus Lipid-Lowering Therapy for HTG-AP

  This trial tests whether adding a probiotic capsule to standard lipid-lowering therapy helps people with mild HTG-AP see lower triglycerides and better recovery.

  Recruiting Phase 4 Zhongshan Hospital Xiamen University · Xiamen, Fujian · NCT07720232

• EHR-guided LDL cholesterol optimization after a heart event

  A pharmacist-guided program using electronic health records to help adults in Alberta reach LDL goals after a heart event by adjusting medications and ordering tests.

  Recruiting at 2 sites University of Alberta · Edmonton, Alberta and 1 other locations · NCT07685639

• Spermidine supplement for lipid and weight changes in adults with obesity and high cholesterol

  This study tests whether taking spermidine daily for 1 month can improve blood lipids and body weight in adults who are overweight or obese with high cholesterol, while monitoring safety.

  Recruiting Shanghai 10th People's Hospital · Shanghai, Shanghai Municipality · NCT07662330

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.